Patents by Inventor Pingli Liu

Pingli Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210128568
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Application
    Filed: September 8, 2020
    Publication date: May 6, 2021
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
  • Publication number: 20210105998
    Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: December 18, 2020
    Publication date: April 15, 2021
    Inventors: Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Publication number: 20210079016
    Abstract: The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 18, 2021
    Inventors: Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
  • Publication number: 20210040090
    Abstract: The present invention relates to salt forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-(3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-ylamino)-2,2?-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, including methods of preparation thereof, where the compound is useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: August 7, 2020
    Publication date: February 11, 2021
    Inventors: Zhongjiang Jia, Pingli Liu, David J. Meloni, Yongchun Pan, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Publication number: 20210030722
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Application
    Filed: April 15, 2020
    Publication date: February 4, 2021
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
  • Patent number: 10899736
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: January 26, 2021
    Assignee: Incyte Corporation
    Inventors: Dengjin Wang, Pingli Liu, Yongzhong Wu, Jiacheng Zhou
  • Publication number: 20210017445
    Abstract: The present invention relates to a carbonate reservoir filtration-loss self-reducing acid fracturing method.
    Type: Application
    Filed: June 24, 2020
    Publication date: January 21, 2021
    Inventors: Weiyu CHEN, Liqiang ZHAO, Zhifeng LUO, Juan DU, Pingli LIU, Nianyin LI, Kun XU
  • Patent number: 10858372
    Abstract: The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: December 8, 2020
    Assignee: Incyte Corporation
    Inventors: Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
  • Patent number: 10799509
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: October 13, 2020
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
  • Publication number: 20200300082
    Abstract: The invention discloses a calculation method for dynamic fluid loss of acid-etched fracture considering wormhole propagation, which is applied to pad acid fracturing process, comprising the following steps: Step 1: dividing the construction time T of injecting acid fluid into artificial fracture into m time nodes at equal intervals, then the time step ?t=T/m and tn=n?t, where, n=0, 1, 2, 3, . . . , m, and to is the initial time; Step 2: calculating the fluid loss velocity vl(0) in the fracture at t0; Step 3: calculating the flowing pressure distribution P(n) in the fracture at tn; Step 4: calculating the width wa(n) of acid-etched fracture at tn; Step 5: calculating the wormhole propagation and the fluid loss velocity vl(n) at tn; Step 6: substituting the fluid loss velocity vl(n) into Step 3, and repeating Step 3 to Step 6 in turn until the end of acid fluid injection.
    Type: Application
    Filed: June 11, 2020
    Publication date: September 24, 2020
    Applicants: SOUTHWEST PETROLEUM UNIVERSITY, PETROCHINA COMPANY LIMITED
    Inventors: Pingli Liu, Xiang Chen, Heng Xue, Honglan Zou, Liqiang Zhao, Nianyin Li, Daocheng Wang, Zhifeng Luo, Juan Du, Chong Liang, Mingyue Cui, Fei Liu, Changlin Zhou, Rong Zeng
  • Publication number: 20200283436
    Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: March 24, 2020
    Publication date: September 10, 2020
    Inventors: Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Patent number: 10626114
    Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: April 21, 2020
    Assignee: Incyte Corporation
    Inventors: Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Publication number: 20190300545
    Abstract: The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
    Type: Application
    Filed: May 29, 2019
    Publication date: October 3, 2019
    Inventors: Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
  • Publication number: 20190233392
    Abstract: This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: January 29, 2019
    Publication date: August 1, 2019
    Inventors: Dengjin Wang, Pingli Liu, Yongzhong Wu, Jiacheng Zhou
  • Patent number: 10364388
    Abstract: The present invention discloses a phase change fracturing fluid system for phase change fracturing, including the following components in percentage by weight: 10%-40% of supramolecular construction unit, 0-40% of supramolecular function unit, 0.5%-2% of surfactant, 0-5% of inorganic salt, 0.5%-2% of oxidizing agent, 0-2% of cosolvent and the remaining of solvent. The supramolecular construction unit is melamine, triallyl isocyanurate, or a mixture thereof. The supramolecular function unit is vinyl acetate, acrylonitrile, or a mixture thereof. The solvent is methylbenzene, ethylbenzene, o-xylene, m-xylene or p-xylene. In the fracturing construction process, a conventional fracturing fluid is used for fracturing a formation first; the phase change fracturing fluid is then injected into the formation, or the phase change fracturing fluid and other fluids which cannot be subjected to phase change are injected into the formation together.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: July 30, 2019
    Assignee: SOUTHWEST PETROLEUM UNIVERSITY
    Inventors: Liqiang Zhao, Yong Yang, Guangyan Du, Donghe Yu, Juan Du, Hang Che, Zhifeng Luo, Guohua Liu, Yuxin Pei, Nianyin Li, Pingli Liu, Kun Xu
  • Patent number: 10329305
    Abstract: The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: June 25, 2019
    Assignee: Incyte Corporation
    Inventors: Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
  • Publication number: 20190167692
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan
  • Publication number: 20190169186
    Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: December 7, 2018
    Publication date: June 6, 2019
    Inventors: Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
  • Patent number: 10301919
    Abstract: A phase-change hydraulic fracturing process, including the following steps: (1) injecting clean water or conventional fracturing fluid to a formation, so that the formation fractures; (2) placing non-phase-change liquid and phase-change liquid in different liquid mixing tanks and injecting into a shaft at the same time, an injection volume ratio of the non-phase-change liquid to the phase-change liquid is (0-0.7):(0.3-1); (3) injecting a displacement fluid into the shaft, so that the non-phase-change liquid and the phase-change liquid in the shaft completely enter a reservoir; (4) performing well shut-in and pressure-out for 30-200 min, so that solid-phase matters generated by the phase-change liquid are laid in the fracture; and (5) relieving pressure to finish the construction.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: May 28, 2019
    Assignee: SOUTHWEST PETROLEUM UNIVERSITY
    Inventors: Liqiang Zhao, Yong Yang, Zhifeng Luo, Donghe Yu, Juan Du, Guohua Liu, Hang Che, Guangyan Du, Yuxin Pei, Nianyin Li, Pingli Liu, Kun Xu, Bingxiao Liu
  • Patent number: 10245265
    Abstract: The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: April 2, 2019
    Assignees: INCYTE INCORPORATION, INCYTE HOLDINGS CORPORATION
    Inventors: Lingkai Weng, Lei Qiao, Jiacheng Zhou, Pingli Liu, Yongchun Pan